Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15054
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.otherUCH. Departamento de Farmacia-
dc.creatorDea Ayuela, María Auxiliadora-
dc.creatorCastillo García, Encarnación-
dc.creatorGonzález Álvarez, Marta-
dc.creatorVega, Celeste-
dc.creatorRolón, Miriam-
dc.creatorBolás Fernández, Francisco-
dc.creatorBorrás, Joaquín-
dc.creatorGonzález Rosende, María Eugenia-
dc.date.accessioned2024-01-23T08:39:11Z-
dc.date.available2024-01-23T08:39:11Z-
dc.date.issued2009-11-
dc.identifier.citationDea-Ayuela, M.A., Castillo, E., Gonzalez-Alvarez, M., Vega, C., Rolón, M., Bolás-Fernández, F., Borrás, J. & González-Rosende, M.E. (2009). In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide. Bioorganic & Medicinal Chemistry, vol. 17, i. 21 (nov.), pp. 7449–7456. DOI: https://doi.org/10.1016/j.bmc.2009.09.030es_ES
dc.identifier.issn0968-0896-
dc.identifier.urihttp://hdl.handle.net/10637/15054-
dc.descriptionEste recurso no está disponible en acceso abierto por política de la editorial.-
dc.description.abstractA series of compounds containing the nitrobenzene and sulfonamido moieties were synthesized and their leishmanicidal effect was assessed in vitro against Leishmania infantum promastigotes. Among the compounds evaluated, the p-nitrobenzenesulfonamides 4Aa and 4Ba, and the p-nitroaniline 5 showed significant activity with a good selectivity index. In a Balb/c mice model of L. Infantum, administration of compounds 4Aa, 4Ba or 5 (5 mg/kg/day for 10 days, injected ip route) led to a clear-cut parasite burden reduction (ca. 99%). In an attempt to elucidate their mechanism of action, the DNA interaction of 4Aa and 5 was investigated by means of viscosity studies, thermal denaturation and nuclease activity assay. Both compounds showed nuclease activity in the presence of copper salt. The results suggest that compounds 4Aa, 4Ba and 5 represent possible candidates for drug development in the therapeutic control of leishmaniasis.es_ES
dc.language.isoenes_ES
dc.publisherElsevieres_ES
dc.relationEste artículo de investigación ha sido financiado por la Generalitat Valenciana (GVPRE2008/77) y por la Universidad CEU Cardenal Herrerra (PRCEU-UCH08–07). También ha recido financiación a través del CYCIT (CTQ2007–63690/BQU).-
dc.relationUCH. Financiación Autonómica-
dc.relationUCH. Financiación Universidad-
dc.relation.ispartofBioorganic & Medicinal Chemistry, vol. 17, i. 21 (nov.)-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.es-
dc.subjectEnfermedad transmisible-
dc.subjectInfectious diseases-
dc.subjectTratamiento médico-
dc.subjectMedical treatment-
dc.subjectMedicamento-
dc.subjectDrugs-
dc.subjectFarmacología-
dc.subjectPharmacology-
dc.titleIn vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamidees_ES
dc.typeArtículoes_ES
dc.identifier.doihttps://doi.org/10.1016/j.bmc.2009.09.030-
dc.relation.projectIDGVPRE2008/77-
dc.relation.projectIDPRCEU-UCH08–07-
dc.relation.projectIDCTQ2007–63690/BQU-
dc.centroUniversidad Cardenal Herrera-CEU-
Aparece en las colecciones: Dpto. Farmacia




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.